Effects of fluvastatin on human biliary lipids

Tazuma, Susumu; Ohya, Tatsuo; Mizuno, Takemi; Takizawa, Itsuo; Kunita, Toshio; Takata, K.; Hayashi, Kakeru; Hino, Fumiaki; TOKUMO, H; Watanabe, T.

doi:10.1016/s0002-9149(06)80024-x

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based upon the understandings of defects of metabolism in gallstone diseases, agents for dyslipidemias are reported in this regard. Taken together, statins are promising for an adjuvant, not to worsen bile cholesterol metastability . In contrast, fibrates, a ligand for nuclear receptors, enhance the phospholipid secretion into bile, and cholesterol in vesicles is physicochemically stabilized …”

Section: Gallstone and Lipid Metabolismmentioning

confidence: 99%

Nutritional factors (nutritional aspects) in biliary disorders: Bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction

Tazuma

Kanno

Sugiyama

et al. 2013

J of Gastro and Hepatol

View full text Add to dashboard Cite

Nutritional factors play a key role in the pathogenesis of biliary diseases such as gallstones and pancreaticobiliary maljunction. Gallstones are primarily classified into cholesterol stone and pigment stone according to the major composition. Cholesterol gallstone formation is very likely based upon supersaturated bile formation, and pigment stones are formed in bile rich in bilirubin. Thus, defects of hepatic metabolism of lipids and organic anions lead to biliary stones. Here, the recent understanding of cholesterol gallstone pathogenesis is elaborated. On the other hand, there is another important link of biliary lipid degradation to serious biliary disease, namely pancreaticobiliary maljunction. Lysophosphatidylcholine (lysoPC), a derivative of phosphatidylcholine hydrolysis by phospholipase A2, is a highly abundant bioactive lipid mediator present in circulation as well as in bile. Increases in bile of lysoPC and phospholipase A2 have been reported in pancreaticobiliary maljunction and considered to be the major risk factor for biliary tract cancers. Further, oxidized fatty acids have been established as a potent ligand for G2A, a member of G protein-coupled receptor family that mediates a diverse array of biological processes including cell growth and apoptosis. Thus, both of lysoPC and free fatty acids are supposed to play an important role through G2A in biliary inflammation and carcinogenesis of pancreaticobiliary maljunction. Taken together, nutritional factors, especially lipid compounds, are seemingly crucial in the pathogenesis of biliary diseases, and such a causal relationship is reviewed by mainly authors' previous publications.

show abstract

Section: Gallstone and Lipid Metabolismmentioning

confidence: 99%

Nutritional factors (nutritional aspects) in biliary disorders: Bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction

Tazuma

Kanno

Sugiyama

et al. 2013

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…26 Reports on alterations in human bile cholesterol saturation after statin therapy showed evidence that statin medications decreased the cholesterol saturation of bile when bile was sampled and analyzed at the time of cholecystectomy, 28,29 although results of other reports did not confirm this association. 30,31 Animal studies are conflicting on the effects of statin medications in the prevention of gallstone formation. 8,9 One study did not find that simvastatin changed gallstone formation or biliary cholesterol crystals in a prairie dog model.…”

Section: Discussionmentioning

confidence: 99%

Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] FLU is used in the treatment of hypercholestrolemia, 5,6 and treatment with statin drugs decreases the risk of cardiovascular diseases, in addition to mortality. 7 FLU has been determined by high performance liquid chromatographic methods with UV detection, 8 fluorometric detection [9][10][11][12] and mass spectrometric detection 13,14 in human plasma.…”

Section: Fluvastatin (Flu) (3r5s6e)-rel-7-[3-(4-fluorophenyl)-1-(1mentioning

confidence: 99%

Development and validation of a GC-FID assay for determination of fluvastatin in pharmaceutical preparations

Aslan¹,

Ersoy²

2009

Quím. Nova

View full text Add to dashboard Cite

Recebido em 1/12/08; aceito em 24/5/09; publicado na web em 30/10/09 A gas chromatographic method has been developed for the assay of fluvastatin sodium (FLU). FLU was silylated with N,Obis(trimethylsilyl)trifluoroacetamide-1% trimethylchlorosilane at 90 ºC for 30 min and analysed in a DB-1 column by capillary gas chromatograph with a flame ionization detector. The method was validated. The assay was linear over the concentration range at 10.0 to 50.0 mg mL -1. The limit of detection and the limit of quantitation were 1.0 and 3.0 mg mL -1 , respectively. The recoveries of FLU derivatives were in the range of 99.25-99.80%. In inter-day and intra-day analysis, the values of relative standard deviation (%) and the relative mean error (%) were found between 0.20-0.80% and -0.20-0.75%, respectively. The developed method was succesfully applied to analyze the FLU content in tablet formulation. The results were statistically compared with those obtained by the official method, and no significant difference was found between the two methods. Therefore, it can be recommended for the quality control assay of FLU in pharmaceutical industry.

show abstract

Effects of fluvastatin on human biliary lipids

Cited by 3 publications

References 0 publications

Nutritional factors (nutritional aspects) in biliary disorders: Bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction

Nutritional factors (nutritional aspects) in biliary disorders: Bile acid and lipid metabolism in gallstone diseases and pancreaticobiliary maljunction

Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures

Development and validation of a GC-FID assay for determination of fluvastatin in pharmaceutical preparations

Contact Info

Product

Resources

About